Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin Safety and PK in Renal Impairment
NCT02647918Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Dec 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotagliflozin in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Number of treatment emergent adverse events. Started Dec 2015; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02647918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647918.